Equitable Trust Co. Has $1.27 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Equitable Trust Co. increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,368 shares of the company’s stock after acquiring an additional 519 shares during the period. Equitable Trust Co.’s holdings in IDEXX Laboratories were worth $1,270,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. TD Asset Management Inc grew its stake in IDEXX Laboratories by 12.2% during the second quarter. TD Asset Management Inc now owns 329,511 shares of the company’s stock worth $176,730,000 after purchasing an additional 35,798 shares during the period. Wilmington Savings Fund Society FSB grew its stake in IDEXX Laboratories by 9.5% during the second quarter. Wilmington Savings Fund Society FSB now owns 2,071 shares of the company’s stock worth $1,111,000 after purchasing an additional 179 shares during the period. RFG Advisory LLC boosted its holdings in IDEXX Laboratories by 5.7% in the second quarter. RFG Advisory LLC now owns 6,776 shares of the company’s stock worth $3,634,000 after acquiring an additional 366 shares in the last quarter. Perfromance Wealth Partners LLC grew its stake in IDEXX Laboratories by 28.2% in the second quarter. Perfromance Wealth Partners LLC now owns 3,746 shares of the company’s stock valued at $2,009,000 after acquiring an additional 825 shares during the period. Finally, NorthRock Partners LLC grew its stake in IDEXX Laboratories by 84.0% in the second quarter. NorthRock Partners LLC now owns 1,906 shares of the company’s stock valued at $1,022,000 after acquiring an additional 870 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IDXX. Piper Sandler reissued a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Jefferies Financial Group began coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective for the company. BTIG Research raised their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $656.50.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $636.91 on Wednesday. The business’s fifty day simple moving average is $640.40 and its 200 day simple moving average is $545.72. The firm has a market capitalization of $50.96 billion, a P/E ratio of 53.03, a price-to-earnings-growth ratio of 4.10 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the sale, the executive vice president directly owned 16,807 shares in the company, valued at $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. Company insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.